Across 257 Phase III immunology trials authorized in 2024–2026, the European site network is highly concentrated: five countries account for 4,753 of 6,748 country-site slots (70.4%). Assistance Publique Hopitaux De Paris is the leading named site organization with 174 trial-site participations, while Poland carries the largest planned participant allocation with 7,039 of 40,477 participants (17.4%). Monoclonal antibodies and small molecules dominate the modality mix, and CRO use rises sharply with operational scale.
The top 10 named site organizations contribute 624 trial-site participations. France dominates the top tier, with 6 of the top 10 sites, followed by Spain with 2 of the top 10.
| Site organization | Country | Participations | Share of trials | Most frequent indications |
|---|---|---|---|---|
| 1. Assistance Publique Hopitaux De Paris | France | 174 | 67.7% | Hemophagocytic lymphohistiocytosis, Systemic lupus erythematosus |
| 2. Hospital Universitari Vall D Hebron | Spain | 67 | 26.1% | Systemic lupus erythematosus, IgA nephropathy |
| 3. Centre Hospitalier Universitaire De Toulouse | France | 58 | 22.6% | Systemic lupus erythematosus, Lupus nephritis |
| 4. Charite Universitaetsmedizin Berlin KöR | Germany | 57 | 22.2% | Psoriatic arthritis, Hereditary angioedema |
| 5. Centre Hospitalier Universitaire De Lille | France | 50 | 19.5% | Hereditary angioedema, Systemic lupus erythematosus |
| 6. Hospices Civils De Lyon | France | 50 | 19.5% | Microscopic polyangiitis, Granulomatosis with polyangiitis (Wegener's) |
| 7. Hospital Universitario Y Politecnico La Fe | Spain | 47 | 18.3% | Allergic rhinitis/rhinoconjunctivitis, Generalized myasthenia gravis |
| 8. Centre Hospitalier Universitaire De Bordeaux | France | 44 | 17.1% | Lupus nephritis, Systemic lupus erythematosus |
| 9. Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Italy | 40 | 15.6% | Systemic lupus erythematosus, Sjögren's syndrome |
| 10. Centre Hospitalier Regional De Marseille | France | 37 | 14.4% | Septic shock, Lupus nephritis |
For sponsors planning late-stage immunology studies, France and Spain supply the densest repeat-participation site layer. AP-HP is an outlier because its 174 participations equal 67.7% of the trial count, far ahead of Vall d'Hebron at 67 participations.
France leads on country-site slots with 1,193 of 6,748 (17.7%), while Poland leads planned participants with 7,039 of 40,477 (17.4%). The five largest site countries together hold 70.4% of country-site slots.
Country choice changes depending on whether the bottleneck is site activation or enrollment capacity. France and Spain provide the broadest site networks, but Poland is the strongest patient-allocation market despite ranking third by site slots.
The dataset contains 142 trials in 2024, 87 in 2025, and 28 in 2026. The 2024 cohort accounts for 4,163 of 6,748 site slots (61.7%) and 22,840 of 40,477 planned participants (56.4%).
The heaviest authorized capacity sits in 2024, but 2026 remains strategically relevant because 28 trials already include 5,134 planned participants, equal to 12.7% of total planned participants in the analyzed period.
Systemic lupus erythematosus is the most frequent disease label, appearing in 25 of 257 trials (9.7%). Allergic rhinitis/rhinoconjunctivitis appears in 18 trials (7.0%), followed by psoriatic arthritis in 13 trials (5.1%).
The Phase III immunology portfolio is not a single-indication market. Autoimmune systemic disease, allergy, dermatology, gastroenterology, and nephrology indications all appear in the top tier, so site selection should be indication-specific rather than therapy-area generic.
Monoclonal antibodies appear in 114 of 257 trials (44.4%), and small molecules appear in 102 of 257 trials (39.7%). Subcutaneous administration is the most common route signal, appearing in 104 trials (40.5%), ahead of oral and intravenous routes.
Late-stage immunology remains biologics-heavy, but small molecules are nearly as common as monoclonal antibodies. This mix affects site capability requirements: subcutaneous drug handling, oral adherence workflows, and intravenous infusion capacity all matter.
Most Phase III immunology trials are randomized: 179 of 257 (69.6%). Open-label trials account for 98 of 257 (38.1%), paediatric trials for 81 of 257 (31.5%), and orphan-drug trials for 42 of 257 (16.3%).
The operational burden is driven less by adaptive or biomarker-stratified design and more by randomized execution, paediatric inclusion, and large country networks. That favors sites with mature consent, randomization, drug accountability, and specialty-clinic throughput.
CROs are present in 164 of 257 trials (63.8%). CRO use rises from 7 of 42 trials with 1–5 sites (16.7%) to 37 of 42 trials with 51+ sites (88.1%), and from 8 of 67 one-country trials (11.9%) to 42 of 45 trials with 11+ countries (93.3%).
| Site complexity | Trials | CRO trials | CRO use | Sites | Patients |
|---|---|---|---|---|---|
| 1–5 sites | 42 | 7/42 | 16.7% | 91 | 4,353 |
| 6–10 sites | 24 | 12/24 | 50.0% | 177 | 1,807 |
| 11–25 sites | 69 | 43/69 | 62.3% | 1,225 | 7,479 |
| 26–50 sites | 65 | 50/65 | 76.9% | 2,420 | 9,585 |
| 51+ sites | 42 | 37/42 | 88.1% | 2,835 | 13,128 |
| Country complexity | Trials | CRO trials | CRO use | Sites | Patients |
|---|---|---|---|---|---|
| 1 country | 67 | 8/67 | 11.9% | 885 | 10,831 |
| 2–5 countries | 70 | 45/70 | 64.3% | 1,088 | 6,571 |
| 6–10 countries | 66 | 60/66 | 90.9% | 2,369 | 10,506 |
| 11+ countries | 45 | 42/45 | 93.3% | 2,406 | 11,925 |
The complexity threshold is clear: CRO usage becomes the dominant model once trials exceed 10 sites or 5 countries. IQVIA appears in 66 trials (25.7%), ICON in 57 (22.2%), Parexel in 39 (15.2%), and PPD/Thermo Fisher in 34 (13.2%).
The top five sponsors account for 76 of 257 trials (29.6%). Janssen-Cilag International leads by trial count with 24 trials (9.3%), while Novartis Pharma leads the single-name site footprint among the top sponsors with 645 country-site slots.
| Sponsor | Trials | Share of trials | Country-site slots |
|---|---|---|---|
| Janssen-Cilag International | 24 | 9.3% | 953 |
| Novartis Pharma | 18 | 7.0% | 645 |
| Sanofi-Aventis R&D | 13 | 5.1% | 372 |
| AbbVie | 11 | 4.3% | 320 |
| Assistance Publique Hopitaux De Paris | 10 | 3.9% | 257 |
| UCB Biopharma | 9 | 3.5% | 290 |
| Argenx | 8 | 3.1% | 210 |
The sponsor landscape is fragmented: even the largest sponsor group covers fewer than 10% of trials. Competitive feasibility work should therefore benchmark both high-volume pharma sponsors and major academic/public sponsors such as AP-HP.
A trial-site participation means a named site organization appearing in a trial site roster. A country-site slot means the country-level site count reported for a trial-country pair. Planned participants are country-level planned participant allocations. Percentages use the 257-trial denominator unless a section states a country, site, or complexity-specific denominator.